Exopharm Ltd (ex1) Logo

Exopharm Ltd (EX1)

___:___ · Healthcare

EX1 Chart


EX1's Principal Activity is the investment in biopharmaceutical drug development.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +23.86%
vs ASX 200 (1yr) +5.55%


Market Capitalisation
ASX Rank 1,132 of 2,319
Sector Rank 99 of 199

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies IBX / PAB / RNO
EPS -$0.065
DPS $0.00
NTA per share $0.11

Broker Consensus

EX1 is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Exopharm Limited (EX1) is a clinical-stage Australian exosome medicine company developing naive exosome products for regenerative medicine and engineered exosomes for new precision medicines. Exopharm owns a purification technology called Ligand-based Exosome Affinity Purification (LEAP).

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Melbourne VIC 3000
Website www.exopharm.com
Registry Automic Group
Auditor William Buck Audit (VIC) Pty Ltd
Date Listed 18 Dec 2018

Upcoming Calendar (Forecasted)

No calendar entries available.

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr David James Franks Company Secretary Sep 2021
Dr Jennifer (Jenn) King Non-Executive Director Sep 2021 Director Bio icon

Dr Jennifer (Jenn) King

Non-Executive Director

Dr King has experience in Pharmaceuticals and Biotechnology, having been Director, New Product Marketing in Shire Human Genetic Therapies, Senior Director Business Development & Licensing of Shire Pharmaceuticals supporting the rare disease business unit. More recently Jenn served as the Senior Vice President, Business Development of Intellia Therapeutics Inc., a pioneering company focused on the development of CRISPR/Cas9 genome editing therapies for patients with severe diseases. She has been involved in the emergence of nucleic acid medicines (DNA and RNA) within both Pharma and Biotech. With a network in North America, Jenn currently works as an independent consultant to a select group of emerging international biotechnology companies. She also served as a member of the Exopharm's Advisory Panel.

Ms Elizabeth McGregor Non-Executive Director Jan 2021 Director Bio icon

Ms Elizabeth McGregor

Non-Executive Director

Ms McGregor currently works at the Automic Group and is a Company Secretary for a number of ASX listed entities.

Mr Jason Mark Watson Non-Executive Chairman,Non-Executive Director Aug 2018 Director Bio icon

Mr Jason Mark Watson

Non-Executive Chairman,Non-Executive Director

Mr Watson has board and advisory experience acting with small and medium-sized enterprises, research institutes and listed companies in the life sciences and other sectors. Mr Watson has assisted companies in developing, commercialising and transacting technologies through biotechnology licensing deals. Mr Watson is principal of Elementary Law. His practice is on assisting clients achieve the outcomes for their patents and innovations, including through corporate fund raising, protection strategies, licensing and commercialisation. Mr Watson has experience in relation to transactions, including establishing multi-party engagements, research and consultancy contracts and negotiating and implementing clinical trial, licensing, assignment, manufacturing, shareholding and other commercial arrangements.

Dr Ian Edward Dixon Managing Director May 2013 Director Bio icon

Dr Ian Edward Dixon

Managing Director

Dr Dixon co-Founded Cynata Inc in 2011. Dr Dixon is a co-inventor of the LEAP Technology. Dr Dixon brings to the Board technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development.

Christopher Baldwin Chief Commercial Officer N/A
Gregory Lichtfuss Chief Operating Officer N/A

Director Transactions

EX1 directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
02/09/21 Elizabeth McGregor Buy +30,000 $0.54 $16,200 On-market trade
01/09/21 Ian Dixon Buy +83,333 $0.535 $44,583 Conversion of securities
01/09/21 Ian Dixon Exercise 83,333 $0.535 $44,583 Conversion of securities
01/09/21 Jason Watson Buy +30,000 $0.535 $16,050 Conversion of securities
01/09/21 Jason Watson Exercise 30,000 $0.535 $16,050 Conversion of securities
22/12/20 Jason Watson Buy +60,000 $0.328 $19,650 Off-market trade
02/12/20 Ian Dixon Issued 200,000 $0.36 $72,000 Issue of securities
09/11/20 Jason Watson Issued 90,000 $0.36 $32,400 Issue of securities
09/11/20 Ian Dixon Issued 250,000 $0.36 $90,000 Issue of securities
13/09/19 Jason Watson Issued 100,000 $0.37 $37,000 Placement
19/08/19 Jason Watson Buy +40,000 $0.37 $14,800 Participation in share purchase plan
19/08/19 David Parker Buy +20,000 $0.37 $7,400 Participation in share purchase plan
19/08/19 Ian Dixon Buy +40,000 $0.37 $14,800 Participation in share purchase plan

Director Interests

The current holdings of EX1 directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Elizabeth McGregor 02/09/2021 30,000 N/A N/A N/A
Jennifer (Jenn) King 01/09/2021 0 N/A N/A N/A
Jason Watson 01/09/2021 N/A 380,000 N/A N/A
Ian Dixon 01/09/2021 N/A 28,258,627 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Aug 24, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Altnia Holdings Pty Ltd 27,975,294 29.30%
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon 2,276,849 2.38%
Oldview Enterprises Pty Ltd 1,432,585 1.50%
Kohen Enterprises Pty Ltd 1,350,000 1.41%
Anthony John Locantro 1,330,000 1.39%
Phytose Corporation Pty Limited 1,176,471 1.23%
Carda Pty Ltd 1,170,000 1.23%
Mrs Anna Felicia Belton 1,023,334 1.07%
Zessham Pty Ltd 950,000 1.00%
Acns Capital Markets Pty Ltd 800,000 0.84%
Drp 2006 Super Pty Ltd 760,000 0.80%
Saintly Company Pty Ltd 636,000 0.67%
Kyriaco Barber Pty Ltd 635,000 0.67%
Mr John Gardner 600,271 0.63%
Gregor Lichtfuss 588,235 0.62%
Jeccs Pty Ltd 545,000 0.57%
Mr Wayne John Hogan & Mrs Angela Patrice Hogan 500,000 0.52%
Ringsford Pty Ltd 500,000 0.52%
Mr Andrew Stewart Coles & Ms Alexandra Constance Manook 475,000 0.50%
Aukera Capital Pty Ltd 460,000 0.48%

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Altnia Holdings Pty Ltd 30/06/2020 27,935,294 29.33
Carl Charalambous 27/01/2021 8,653,912 6.21
Ian E Dixon 30/04/2021 28,175,294 18.05

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
30-04-21 Ian E Dixon 200,000 20.09 18.05
27-01-21 Carl Charalambous 1,400,084 5.20 6.21
21-12-20 Carl Charalambous 7,253,828 -- 5.20

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.25 30 June
2019 $0.41 28 June
Page Icon
EX1 Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.